GlassScriptPhysician profile
Carl N Liedman
NPI 1164427910
$1,144.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $170.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $252.03 | 2019 | |
| Lilly USA, LLC | $227.25 | 2019-2020 | |
| Abbvie INC. | $64.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.03 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.15 | 2019 | |
| Novo Nordisk INC | $36.62 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.99 | 2019 | |
| Sanofi Pasteur INC. | $27.41 | 2019-2020 | |
| Mannkind Corporation | $21.62 | 2019 | |
| Seqirus USA INC | $17.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Liedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.